By 2030, it is anticipated that the China Radiotherapy Market will reach a value of $991 Mn from $555 Mn in 2022, growing at a CAGR of 7.5% during 2022-30. The Radiotherapy Therapeutics Market in China is dominated by a few domestic players such as Sinopharm, Accuray China Medical Equipment, and Shanghai Elekta Medical Equipment. The radiotherapy market in China is segmented into different types, technologies, procedures, applications, and end-users. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for China Radiotherapy is increasing on account of the rise in cancer cases in the country.
This report presents a strategic analysis of the China Pain Management Devices Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the China Pain Management Devices Market, offering unmatched value, accuracy, and expert insights.
This report presents a strategic analysis of the China Obesity Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the China Obesity Drugs Market, offering unmatched value, accuracy, and expert insights.
This report presents a strategic analysis of the China Medical and Diagnostic Laboratory Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the China Medical and Diagnostic Laboratory Service Market, offering unmatched value, accuracy, and expert insights.
China's Lung Cancer Drug Market is projected to grow from $0.769 Bn in 2022 to $1.624 Bn by 2030, registering a CAGR of 9.8% during the forecast period of 2022-30. Lung cancer is the most commonly diagnosed cancer in China, and the incidence of lung cancer is increasing in the country, likely due to factors such as smoking and exposure to environmental pollutants. The China lung cancer drug market is dominated by a few large players, including Pfizer, AstraZeneca, and Roche.
By 2030, it is anticipated that the China Liver Disease Therapeutics market will reach a value of $3.23 Bn from $1.85 Bn in 2022, growing at a CAGR of 7.2% during 2022-30. Liver Disease Therapeutics in China is dominated by a few domestic pharmaceutical companies such as Simcere, Beijing, and Fosun Pharma. The Liver Disease Therapeutics market in China is segmented into different types of disease and different therapy types. Some of the major factors affecting the China Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
This report presents a strategic analysis of the China Healthcare Diagnostics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the China Healthcare Diagnostics Market, offering unmatched value, accuracy, and expert insights.
China's ENT Devices Market is projected to grow from $1.86 Bn in 2022 to $3.26 Bn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The rising prevalence of ENT disorders, such as hearing loss, sinusitis, and tonsillitis, is a major driver of the ENT device market. The market is highly competitive, with a large number of players operating in the space, ranging from small, specialized companies to large multinational corporations. The domestic key players in the China ENT devices market include Beijing Konted Medical Technology, Xuzhou Hengda Electronic, and Shenzhen.
China's depression therapeutics market is expected to witness growth from $812 Mn in 2022 to $1,364 Mn in 2030 with a CAGR of 6.7% for the forecasted year 2022-30. The rising prevalence of mental health disorders especially depression in China and the consequent increased demand for therapeutic options for treatment in China are responsible for the growth of the market. The China depression therapeutics market is segmented by drug type, therapies, indication, and end users. Walvax Biotechnology, Shanghai Pharmaceuticals, and AstraZeneca are the major players in the China depression therapeutics market.
China's Coronary Stents Market is expected to witness growth from $908 Mn in 2022 to $1475 Mn in 2030 with a CAGR of 6.25% for the forecasted year 2022-30. In China, procedures involving coronary stents are completely minimally invasive, which means the patient has less pain and requires smaller incisions. The need for coronary stent surgeries has increased as a result in the country. The market is segmented by type, by mode of delivery, by materials and by end user. Some key players in this market include Lepu Medical Technology, MicroPort, B. Braun, Abbott Laboratories, Biotronik, Medtronic, GE Healthcare, Boston Scientific and Philips Healthcare.
China's Contraceptive Devices Market is expected to witness growth from $1037 Mn in 2022 to $2143 Mn in 2030 with a CAGR of 9.50% for the forecasted year 2022-30. In China, there is an increasing demand for contraceptive methods due to a growing understanding of the advantages of family planning. This is influenced by things like rising urbanization, women's emancipation, and government programs to slow population increase. The market is segmented by type and by gender. Some key players in this market include Suzhou Medical Supplies, Xian Janssen Pharmaceutical, Mylan Laboratories, Shenzhen Huikang Medical Apparatus, CooperSurgical, Pfizer, Pregna International, and Teva Pharmaceutical.
China's biosimilar market size was valued at $1.54 Bn in 2022 and is estimated to expand at a CAGR of 23.7% from 2022 to 2030 and will reach $8.46 Bn in 2030. The market is segmented by product type and indication type. The China biosimilar market will grow as the Chinese biosimilar market is driven by its cost-effective manufacturing capabilities. The key market players are Bio-Thera Solutions (CHN), Innovent Biologics (CHN), Shanghai Henlius Biotech (CHN), MabSpace Biosciences Co. (CHN), and others.
China's anti-aging therapeutics market is projected to grow from $49 Mn in 2022 to $183 Mn in 2030 with a CAGR of 18.03% for the year 2022-30. As China has the fastest-growing elderly population in the world, the market is projected to expand during the forecast period. Further, the concerns over the appearance of social media among the young Chinese population are also responsible for the growth of the market. The China anti-aging therapeutics market is segmented by product, treatment, target group, type of aging, type of molecules, mechanism of action, ingredient, and by distribution channel. Some of the top players in the market include Harbour BioMed, Hua Medicine, and Rejuvenate Bio.
China's over-the-counter (OTC) pharmaceuticals market size was valued at $11053.3 Mn in 2022 and is estimated to expand at a CAGR of 7.04% from 2022 to 2030 and will reach $19048.4 Mn in 2030. OTC are non-prescription medications and are a vital component of the healthcare system, offering consumers accessible solutions for a wide range of common health issues. The market is segmented by product type and distribution channel. The key market players are Johnson and Johnson Services Inc (USA), Bayer AG (Germany), Novartis AG (Switzerland) and others.
China artificial intelligence (AI) in medical Imaging market size was valued at $121 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 36.9% from 2022 to 2030 and will reach $ 1488. The market is segmented by AI technology, solution, modality, application, and end User. Due to developments in AI and machine learning algorithms that are enabling the creation of more precise and effective medical imaging software, the China Artificial Intelligence (AI) in the Medical Imaging market will expand. Some of the key players in this market are Infervision (CHN), Yitu Healthcare (CHN), 12 Sigma Technologies (CHN), Huiying Medical Technology (CHN), Deepwise (CHN), United Imaging (CHN), Airdoc(CHN), IBM Watson Health (USA), NVIDIA Corporation (USA), and others.
China's Anemia drugs market was valued at 1.28 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.4% from 2022 to 2030 and will reach $2.83 Bn in 2030. One of the main reasons propelling the growth of this market is an increase in income and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Roche, Novartis, Sanofi, Shanghai Pharmaceuticals, Sinopharm Group, Jiangsu Hengrui Medicine, and Guangzhou Baiyunshan Pharmaceutical among others.
The China Healthcare Financial Analytics market size was valued at $xx Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 8.3% from 2022 to 2030 and will reach $xx Mn in 2030. The market is segmented by type, component, and deployment. China’s Healthcare Financial Analytics market will grow as the adoption of technology in the healthcare industry is increasing in China, which is driving demand for healthcare financial analytics solutions. The key market players are Yitu Healthcare, Infervision, United Imaging, Wision AI, Yidu Cloud, Ping An Healthcare and Technology Company, BGI Genomics, and others.
China's electronic records management solutions market size was valued at $xx Mn in 2022 and is estimated to expand at a CAGR of xx% from 2022 to 2030 and will reach $xx Mn in 2030. The market is segmented by solution and deployment. The Chinese government has put in place a number of programs to encourage the use of electronic records management tools. The "Digital China" policy, for instance, seeks to digitize all governmental services and encourage the growth of digital infrastructure. The key market players are Wuhan Baocheng Technology, Beijing Wisdom Watch Information Technology, Beijing Sanxia Technology Development, and others.
This report presents a strategic analysis of the China Women's Health Diagnostic Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the China Women's Health Diagnostic Market, offering unmatched value, accuracy, and expert insights.
China's Retail Pharmacy Market is projected to grow from $83.49 Bn in 2022 to $159.17 Bn by 2030, registering a CAGR of 8.4% during the forecast period of 2022–30. Advancements in technology such as electronic prescriptions, telemedicine, online ordering, and home delivery services are driving the market growth. There are some of the major companies operating in the US Retail Pharmacy Market include Sinopharm, Yonghui Superstores, and Wal-Mart.
China's patient engagement solutions market is projected to grow from $1.37 Bn in 2022 to $3.82 Bn by 2030, registering a CAGR of 13.7% during the forecast period of 2022-30. The main factors driving the growth would be the aging population, chronic disease management, increasing healthcare spending, and government support. The market is segmented by component, delivery mode, application, therapeutic area, functionality, and end-user. Some major players include JD Health, Vecoton, Ping An Good Doctor, Oracle, and Lincor.
China's Neurology Device Market size is at around $1.01 Bn in 2022 and is projected to reach $2.07 Bn in 2030, exhibiting a CAGR of 9.3% during the forecast period (2022-2030). China is a leading manufacturer and simultaneous consumer of neuro devices attributed to its dominance in research and manufacturing excellence by major players like Mindray Medical International, Medtronic, JinkoSolar Holding, and Lepu Medical Technology. This report by Insights10 is segmented by product type like neurostimulation, interventional neurology, neurosurgery devices, and neuro-endoscopes, and by the end user.
This report presents a strategic analysis of the China Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the China Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market, offering unmatched value, accuracy, and expert insights.
China's acne therapeutics market is expected to witness growth from $806 Mn in 2022 to $1,515 Mn in 2030 with a CAGR of 8.2% for the forecasted year 2022-30. The main market drivers of this market are growing sedentary lifestyles and demand for minimally invasive cosmetic treatment in China. The market is segmented by treatment, route of administration, age group, and distribution channel. Botanix Pharmaceuticals, Galderma, and Bausch are some of the key players in the China acne therapeutics market.
China's 3D printing medical devices market size was valued at $239 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 17.8% from 2022 to 2030 and will reach $ 885 Mn in 2030. The market is segmented by component, application, technology, and end user. The China 3D Printing Medical Devices market will grow as the 3D printing technology allows for the customization of medical devices, which is becoming increasingly important in the healthcare industry. The key market players are Tiertime, Beijing Long Yuan Automated Fabrication System Co., Ltd., Shining 3D, and others.